Arena Pharmaceuticals Inc. released data from its Phase III BLOOM-DM trial of weight loss drug lorcaserin in obese and overweight diabetics on Tuesday, sparking plenty of debate among analysts and investors about whether the new findings would help – or hurt – the company's chances at addressing issues raised in an FDA complete response letter last month. (BioWorld Today)